Portfolio

Aisling Capital invests in products, technologies and businesses that advance health.
In addition to investing in companies developing pharmaceutical, biotechnology and medical products, Aisling invests in businesses that provide drug development, manufacturing and other important services to the healthcare industry.

Portfolio Companies

  • Aclaris Therapeutics, Inc.

    NasdaqGS: ACRS
    Specialty pharmaceutical company, focusing on identifying, developing, and commercializing topical drugs to address various needs in dermatology.

    • Year Invested

      2016

    • Fund

      IV

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      current

    • Location

      Malvern, PA

    • Website

      aclaristx.com

  • Adams Respiratory Therapeutics, Inc.

    Specialty pharmaceutical company engaged in the development, commercialization and marketing of over-the-counter and prescription drugs for the treatment of respiratory disorders

    • Year Invested

      2001

    • Fund

      I

    • Sector

      Consumer

    • Company Status

      acquired

    • Investment Status

      historic

    • Location

      Chester, NJ

    • Website

      rb.com

  • ADMA Biologics, Inc.

    NasdaqCM:ADMA
    Biopharmaceutical company that develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of infectious diseases

    • Year Invested

      2007

    • Fund

      II

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      current

    • Location

      Ramsey, NJ

    • Website

      admabiologics.com

  • Advion, Inc.

    Provider of bioanalytical testing equipment to the pharmaceutical industry

    • Year Invested

      2002

    • Fund

      I

    • Sector

      Services

    • Company Status

      private

    • Investment Status

      historic

    • Location

      Ithaca, NY

    • Website

      advion.com

  • Aeglea BioTherapeutics, Inc.

    NasdaqGM:AGLE
    Biopharmaceutical company developing human enzyme therapeutics for rare genetic diseases

    • Year Invested

      2018

    • Fund

      IV

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      current

    • Location

      Austin, TX

    • Website

      aegleabio.com

  • Agile Therapeutics, Inc.

    NasdaqGM:AGRX
    Women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products

    • Year Invested

      2012

    • Fund

      III

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      historic

    • Location

      Princeton, NJ

    • Website

      agiletherapeutics.com

  • Aimmune Therapeutics, Inc.

    NasdaqGS:AIMT
    Biopharmaceutical company developing desensitization treatments for food allergies

    • Year Invested

      2015

    • Fund

      III

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      current

    • Location

      Brisbane, CA

    • Website

      aimmune.com

  • Ajax Health

    Medical device platform building a diversified portfolio of emerging medical device companies

    • Year Invested

      2017

    • Fund

      IV

    • Sector

      Medical Device

    • Company Status

      private

    • Investment Status

      current

    • Location

      Menlo Park, CA

    • Website

      NA

  • Allos Therapeutics, Inc.

    Biopharmaceutical company engaged in the development and commercialization of anti-cancer therapeutics

    • Year Invested

      2002

    • Fund

      I

    • Sector

      Biopharma

    • Company Status

      acquired

    • Investment Status

      historic

    • Location

      Westminster, CO

    • Website

      sppirx.com

  • Ambit Biosciences Corporation

    Biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat oncology, autoimmune and inflammatory diseases

    • Year Invested

      2001

    • Fund

      I

    • Sector

      Biopharma

    • Company Status

      acquired

    • Investment Status

      historic

    • Location

      San Diego, CA

    • Website

      ambitbio.com

  • Aragon Pharmaceuticals, Inc.

    Oncology drug development company focused on novel therapeutics for prostate and breast cancer

    • Year Invested

      2010

    • Fund

      III

    • Sector

      Biopharma

    • Company Status

      acquired

    • Investment Status

      historic

    • Location

      New Brunswick, NJ

    • Website

      jnj.com

  • Archimica Cooperatief U.A.

    Manufacturer of active pharmaceutical ingredients and late state intermediates for the pharmaceutical industry

    • Year Invested

      2006

    • Fund

      II

    • Sector

      Services

    • Company Status

      acquired

    • Investment Status

      historic

    • Location

      Amsterdam, Netherlands

    • Website

      euticals.com

  • Arcus Biosciences, Inc.

    NYSE:RCUS
    Biotechnology company developing cancer immunotherapies targeting the adenosine and other oncology pathways

    • Year Invested

      2017

    • Fund

      IV

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      current

    • Location

      Hayward, CA

    • Website

      arcusbio.com

  • ARMGO Pharma, Inc.

    Biopharmaceutical company dedicated to the discovery and development of novel small-molecule therapeutics to treat debilitating cardiac, muscular and neurological disorders

    • Year Invested

      2006

    • Fund

      II

    • Sector

      Biopharma

    • Company Status

      private

    • Investment Status

      current

    • Location

      Tarrytown, NY

    • Website

      armgo.com

  • ARMO BioSciences, Inc.

    NasdaqGS:ARMO
    Biotechnology company developing immuno-oncology therapies in combination with standard of care or emerging immunotherapies

    • Year Invested

      2018

    • Fund

      IV

    • Sector

      Biopharma

    • Company Status

      acquired

    • Investment Status

      historic

    • Location

      Redwood City, CA

    • Website

      armobio.com

  • Ascendis Pharma A/S

    NasdaqGS:ASND
    Endocrine-focused biopharmaceutical company developing long-acting human growth hormone for the treatment of pediatric growth hormone deficiency

    • Year Invested

      2016

    • Fund

      IV

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      historic

    • Location

      Hellerup, Denmark

    • Website

      ascendispharma.com

  • Aton Pharma, Inc.

    Biotechnology company focused on the development of novel treatments for cancer

    • Year Invested

      2002

    • Fund

      I

    • Sector

      Biopharma

    • Company Status

      acquired

    • Investment Status

      historic

    • Location

      Tarrytown, NY

    • Website

      merck.com

  • Atreca, Inc.

    NasdaqGS:BCEL
    Biotechnology company developing novel oncology therapeutics based on a deep understanding of the human immune response

    • Year Invested

      2018

    • Fund

      IV

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      current

    • Location

      Redwood City, CA

    • Website

      atreca.com

  • Audentes Therapeutics, Inc.

    NasdaqGM:BOLD
    Biotechnology company developing gene therapy-based treatments in several serious, rare diseases

    • Year Invested

      2017

    • Fund

      IV

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      historic

    • Location

      San Francisco, CA

    • Website

      audentestx.com

  • Auxilium Pharmaceuticals, Inc.

    NasdaqGS:AUXL
    Specialty pharmaceutical company that develops and markets pharmaceutical products for urology and sexual health

    • Year Invested

      2003

    • Fund

      I

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      historic

    • Location

      Chesterbrook, PA

    • Website

      auxilium.com

  • AVANZA Laboratories, LLC

    Contract research organization that provides GLP complaint drug development services for biotechnology and pharmaceutical firms, and government agencies

    • Year Invested

      2009

    • Fund

      II

    • Sector

      Services

    • Company Status

      acquired

    • Investment Status

      historic

    • Location

      Gaithersburg, MD

    • Website

      smithersavanza.com

  • AVROBIO, Inc.

    NasdaqGS:AVRO
    Biotechnology company developing lentiviral-based gene therapies to treat lysosomal storage disorders (LSDs)

    • Year Invested

      2018

    • Fund

      IV

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      current

    • Location

      Cambridge, MA

    • Website

      avrobio.com

  • Axcan Pharma, Inc.

    Specialty pharmaceutical company focused on the treatment of gastrointestinal disorders

    • Year Invested

      2000

    • Fund

      I

    • Sector

      Biopharma

    • Company Status

      acquired

    • Investment Status

      historic

    • Location

      Quebec, Canada

    • Website

      actavis.com

  • Barrier Therapeutics, Inc.

    Specialty pharmaceutical company focused on development and commercialization of dermatology drugs

    • Year Invested

      2002

    • Fund

      I

    • Sector

      Biopharma

    • Company Status

      acquired

    • Investment Status

      historic

    • Location

      Princeton, NJ

    • Website

      stiefel.com

  • Bioenvision, Inc.

    Biotechnology company focused on the development and commercialization of drugs to treat oncology and infectious disease

    • Year Invested

      2002

    • Fund

      I

    • Sector

      Biopharma

    • Company Status

      acquired

    • Investment Status

      historic

    • Location

      New York, NY

    • Website

      genzyme.com

  • Biohaven Pharmaceuticals Ltd.

    NYSE:BHVN
    Biopharmaceutical company developing treatments for orphan neurologic indications and other areas of large unmet medical needs

    • Year Invested

      2016

    • Fund

      IV

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      historic

    • Location

      New Haven, CT

    • Website

      biohavenpharma.com

  • BridgeBio Pharma LLC

    NasdaqGS:BBIO
    Orphan disease drug platform with a robust portfolio of transformative drug programs that address rare diseases across oncology, cardiology, dermatology, neurology and endocrinology

    • Year Invested

      2017

    • Fund

      IV

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      current

    • Location

      Palo Alto, CA

    • Website

      bridgebio.com

  • Cardiokine, Inc.

    Biotechnology company developing drugs for the treatment and prevention of cardiovascular diseases

    • Year Invested

      2004

    • Fund

      I

    • Sector

      Biopharma

    • Company Status

      acquired

    • Investment Status

      historic

    • Location

      Philadelphia, PA

    • Website

      chiesiusa.com

  • Catalent, Inc.

    NYSE:CTLT
    Provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products

    • Year Invested

      2007

    • Fund

      II

    • Sector

      Services

    • Company Status

      public

    • Investment Status

      historic

    • Location

      Somerset, NJ

    • Website

      catalent.com

  • Cempra, Inc.

    NasdaqGS:CEMP
    Drug discovery and development company focused on infectious diseases and the treatment of drug-resistant bacteria

    • Year Invested

      2006

    • Fund

      II

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      historic

    • Location

      Chapel Hill, NC

    • Website

      cempra.com

  • Chimerix, Inc.

    NasdaqGM:CMRX
    Biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need

    • Year Invested

      2013

    • Fund

      III

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      historic

    • Location

      Durham, NC

    • Website

      chimerix.com

  • Cidara Therapeutics, Inc.

    NasdaqGM:CDTX
    Drug discovery and development company focused on devastating fungal infections that often complicate cancer and transplant treatments

    • Year Invested

      2008

    • Fund

      II

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      current

    • Location

      San Diego, CA

    • Website

      cidara.com

  • Clovis Oncology, Inc.

    NasdaqGS:CLVS
    Biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents

    • Year Invested

      2011

    • Fund

      III

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      historic

    • Location

      Boulder, CO

    • Website

      clovisoncology.com

  • CollaGenex Pharmaceuticals, Inc.

    Specialty pharmaceutical company that develops and markets proprietary medical therapies to the dermatology market

    • Year Invested

      2001

    • Fund

      I

    • Sector

      Biopharma

    • Company Status

      acquired

    • Investment Status

      historic

    • Location

      Newton, PA

    • Website

      galderma.com

  • Colorescience, Inc.

    Cosmetics company that manufactures and sells mineral-based products

    • Year Invested

      2012

    • Fund

      I

    • Sector

      Consumer

    • Company Status

      acquired

    • Investment Status

      historic

    • Location

      Carlsbad, CA

    • Website

      colorescience.com

  • Cynapsus Therapeutics Inc.

    NasdaqGM:CYNA
    Specialty pharmaceutical company focused on the treatment of OFF episodes in Parkinson’s disease

    • Year Invested

      2015

    • Fund

      III

    • Sector

      Biopharma

    • Company Status

      acquired

    • Investment Status

      historic

    • Location

      Toronto, Canada

    • Website

      cynapsus.ca

  • Cytos Biotechnology AG

    SWX:CYTN
    Biopharmaceutical company focused on the development of targeted immunotherapies with a VLP B-cell vaccines platform and ongoing preclinical development programs based on the platform

    • Year Invested

      2012

    • Fund

      III

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      historic

    • Location

      Schlieren, Switzerland

    • Website

      cytos.com

  • Dermira, Inc.

    NasdaqGS:DERM
    Specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients

    • Year Invested

      2014

    • Fund

      III

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      historic

    • Location

      Redwood City, CA

    • Website

      dermira.com

  • Durata Therapeutics, Inc.

    Pharmaceutical company focused on the development and commercialization of differentiated therapeutic solutions for physicians and providers to advance patient care in infectious disease and acute illnesses

    • Year Invested

      2009

    • Fund

      III

    • Sector

      Biopharma

    • Company Status

      acquired

    • Investment Status

      historic

    • Location

      Chicago, IL

    • Website

      duratatherapeutics.com

  • EarLens Corporation

    Medical device company committed to providing hearing impaired patients a hearing solution that is designed to change the current standard of care for sound performance.

    • Year Invested

      2014

    • Fund

      III

    • Sector

      Medical Device

    • Company Status

      private

    • Investment Status

      current

    • Location

      Menlo Park, CA

    • Website

      earlenscorp.com

  • Eidos Therapeutics

    NasdaqGS:EIDX
    Biopharmaceutical company developing therapies to treat transthyretin amyloidosis (ATTR), primarily in the heart

    • Year Invested

      2018

    • Fund

      IV

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      current

    • Location

      San Francisco, CA

    • Website

      eidostx.com

  • Esperion Therapeutics, Inc.

    NasdaqGM:ESPR
    Drug discovery and development company focused on therapies that prevent, treat and reverse cardiovascular and metabolic diseases

    • Year Invested

      2008

    • Fund

      II

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      historic

    • Location

      Ann Arbor, MI

    • Website

      esperion.com

  • F2G Limited

    Antifungal drug discovery and development company focused on novel therapies to treat life threatening invasive fungal infections

    • Year Invested

      2016

    • Fund

      IV

    • Sector

      Biopharma

    • Company Status

      private

    • Investment Status

      historic

    • Location

      Manchester, UK

    • Website

      f2g.com

  • Global Blood Therapeutics, Inc.

    NasdaqGS:GBT
    Biopharmaceutical company developing novel therapies to improve the lives of patients with serious blood-based disorders

    • Year Invested

      2016

    • Fund

      IV

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      historic

    • Location

      South San Francisco, CA

    • Website

      globalbloodtx.com

  • GTx, Inc.

    NasdaqCM:GTXI
    Biopharmaceutical company targeting hormone pathways to treat stress urinary incontinence (SUI) in women

    • Year Invested

      2017

    • Fund

      IV

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      historic

    • Location

      Memphis, TN

    • Website

      gtxinc.com

  • Harmony Biosciences, LLC

    Biopharmaceutical company developing and commercializing innovative drugs to address unmet needs for patients with sleep and CNS disorders

    • Year Invested

      2018

    • Fund

      IV

    • Sector

      Biopharma

    • Company Status

      private

    • Investment Status

      current

    • Location

      Plymouth Meeting, PA

    • Website

      harmonybiosciences.com

  • Ibrutinib Royalty

    Anti-cancer drug targeting B-cell malignancies

    • Year Invested

      2013

    • Fund

      III

    • Sector

      Biopharma

    • Company Status

      private

    • Investment Status

      historic

    • Location

      N/A

    • Website

      imbruvica.com

  • Infinity Pharmaceuticals, Inc.

    NasdaqGS:INFI
    Biopharmaceutical company dedicated to discovering, developing and delivering best-in-class medicines to patients with difficult-to-treat diseases

    • Year Invested

      2012

    • Fund

      III

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      historic

    • Location

      Cambridge, MA

    • Website

      infi.com

  • Intercept Pharmaceuticals, Inc.

    NasdaqGS:ICPT
    Biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing our proprietary bile acid chemistry

    • Year Invested

      2012

    • Fund

      III

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      historic

    • Location

      New York, NY

    • Website

      interceptpharma.com

  • Intersect ENT, Inc.

    NasdaqGM:XENT
    Commercial stage drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions

    • Year Invested

      2014

    • Fund

      III

    • Sector

      Medical Device

    • Company Status

      public

    • Investment Status

      historic

    • Location

      Menlo Park, CA

    • Website

      propelopens.com

  • LENSAR, Inc.

    Leader in next-generation femtosecond laser technology for refractive cataract surgery

    • Year Invested

      2008

    • Fund

      II

    • Sector

      Medical Device

    • Company Status

      private

    • Investment Status

      historic

    • Location

      Orlando, FL

    • Website

      lensar.com

  • Lombard Medical, Inc.

    NasdaqGM:EVAR
    Medical technology company specializing in developing, manufacturing and marketing endovascular stent-grafts that address significant unmet needs in the repair of aortic aneurysms

    • Year Invested

      2014

    • Fund

      III

    • Sector

      Medical Device

    • Company Status

      public

    • Investment Status

      historic

    • Location

      Oxfordshire, UK

    • Website

      lombardmedical.com

  • Loxo Oncology, Inc.

    NasdaqGM:LOXO
    Biotechnology company developing targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations

    • Year Invested

      2013

    • Fund

      III

    • Sector

      Biopharma

    • Company Status

      acquired

    • Investment Status

      historic

    • Location

      Stamford, CT

    • Website

      loxooncology.com

  • MAP Pharmaceuticals, Inc.

    Specialty pharmaceutical company developing new therapies based on proprietary drug particle and inhalation technologies

    • Year Invested

      2003

    • Fund

      I

    • Sector

      Biopharma

    • Company Status

      acquired

    • Investment Status

      historic

    • Location

      Mountain View, CA

    • Website

      allergan.com

  • Marker Therapeutics, Inc.

    NasdaqCM:MRKR
    Biotechnology company developing next-generation T cell-based immunotherapies for cancer

    • Year Invested

      2018

    • Fund

      IV

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      current

    • Location

      Houston, TX

    • Website

      markertherapeutics.com

  • MEI Pharma, Inc.

    NasdaqCM:MEIP
    Oncology company focused on the clinical development of novel therapies for cancer

    • Year Invested

      2013

    • Fund

      III

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      historic

    • Location

      San Diego, CA

    • Website

      meipharma.com

  • Menlo Therapeutics Inc.

    NasdaqGS:MNLO
    Biopharmaceutical company developing an oral therapy for the treatment of chronic pruritus associated with various conditions and chronic cough

    • Year Invested

      2017

    • Fund

      IV

    • Sector

      Biopharma

    • Company Status

      private

    • Investment Status

      historic

    • Location

      Menlo Park, CA

    • Website

      menlotherapeutics.com

  • Miramar Labs, Inc.

    OTC:MRLB
    Medical device company focused on developing products for dermatologic medical conditions

    • Year Invested

      2011

    • Fund

      III

    • Sector

      Medical Device

    • Company Status

      acquired

    • Investment Status

      historic

    • Location

      Sunnyvale, CA

    • Website

      miradry.com

  • Myogen, Inc.

    Biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders

    • Year Invested

      2001

    • Fund

      I

    • Sector

      Biopharma

    • Company Status

      acquired

    • Investment Status

      historic

    • Location

      Westminster, CO

    • Website

      gilead.com

  • Nabriva

    NasdaqGM:NBRV
    Biopharmaceutical company developing new antibiotics to treat infectious diseases

    • Year Invested

      2018

    • Fund

      IV

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      current

    • Location

      King of Prussia, PA

    • Website

      nabriva.com

  • NextWave Pharmaceuticals, Inc.

    Specialty pharmaceutical company developing extended release OTC and prescription products for children and adults

    • Year Invested

      2007

    • Fund

      II

    • Sector

      Biopharma

    • Company Status

      acquired

    • Investment Status

      historic

    • Location

      Cupertino, CA

    • Website

      pfizer.com

  • Novazyme Pharmaceuticals, Inc.

    Biotechnology company focused on drugs to treat lysosomal storage diseases

    • Year Invested

      2000

    • Fund

      I

    • Sector

      Biopharma

    • Company Status

      acquired

    • Investment Status

      historic

    • Location

      Princeton, NJ

    • Website

      genzyme.com

  • Nuvation Bio, Inc.

    An oncology drug development company pursuing first-in-class and best-in-class anti-cancer agents

    • Year Invested

      2019

    • Fund

      IV

    • Sector

      Biopharma

    • Company Status

      private

    • Investment Status

      current

    • Location

      New York, NY

    • Website

      NUVATIONBIO.COM

  • ObsEva SA

    NasdaqGS:OBSV
    Biopharmaceutical company developing novel therapeutics in women's health for the treatment of symptoms associated with endometriosis and uterine fibroids

    • Year Invested

      2017

    • Fund

      IV

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      current

    • Location

      Geneva, Switzerland

    • Website

      obseva.com

  • Oculex Pharmaceuticals, Inc.

    Ophthalmic drug delivery company with platform technology to facilitate the treatment of major sight-threatening eye diseases and conditions

    • Year Invested

      2002

    • Fund

      I

    • Sector

      Medical Device

    • Company Status

      acquired

    • Investment Status

      historic

    • Location

      Sunnyvale, CA

    • Website

      allergan.com

  • Paratek Pharmaceuticals, Inc.

    NasdaqGM:PRTK
    Biopharmaceutical company engaged in the discovery, development and commercialization of antibiotics to save lives and alleviate suffering

    • Year Invested

      2007

    • Fund

      II

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      historic

    • Location

      Boston, MA

    • Website

      paratekpharm.com

  • PellePharm

    Biotechnology company developing topical therapeutics targeting rare dermatological diseases

    • Year Invested

      2018

    • Fund

      IV

    • Sector

      Biopharma

    • Company Status

      private

    • Investment Status

      current

    • Location

      San Francisco, CA

    • Website

      pellepharm.com

  • Pernix Therapeutics, Inc.

    NasdaqGM:PTX
    Specialty pharmaceutical company primarily focused on the sales, marketing and development of branded pharmaceutical products

    • Year Invested

      2011

    • Fund

      III

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      current

    • Location

      Houston, TX

    • Website

      pernixtx.com

  • Pharmaron, Inc.

    Provider of research and development services for pharmaceutical and biotechnological industries worldwide

    • Year Invested

      2006

    • Fund

      II

    • Sector

      Services

    • Company Status

      private

    • Investment Status

      historic

    • Location

      Beijing, China

    • Website

      pharmaron.com

  • Planet Biopharmaceuticals, Inc.

    Developer and manufacturer of allergenic extracts and other products for the treatment and prevention of allergy

    • Year Invested

      2007

    • Fund

      II

    • Sector

      Consumer

    • Company Status

      acquired

    • Investment Status

      historic

    • Location

      Liberty, MO

    • Website

      areslifesciences.com

  • Poseida Therapeutics, Inc.

    Biopharmaceutical company developing next-generation CAR-T therapies for hematological cancers and solid tumors

    • Year Invested

      2019

    • Fund

      IV

    • Sector

      Biopharma

    • Company Status

      private

    • Investment Status

      current

    • Location

      San Diego, CA

    • Website

      poseida.com

  • PowerVision, Inc.

    Developer of a fluid-controlled intraocular lens

    • Year Invested

      2014

    • Fund

      III

    • Sector

      Medical Device

    • Company Status

      acquired

    • Investment Status

      historic

    • Location

      Belmont, CA

    • Website

      powervisionlens.com

  • PreCision Dermatology, Inc.

    Specialty pharmaceutical company developing, manufacturing and marketing prescription and consumer dermatology products

    • Year Invested

      2012

    • Fund

      III

    • Sector

      Biopharma

    • Company Status

      acquired

    • Investment Status

      historic

    • Location

      Cumberland, RI

    • Website

      valeant.com

  • Prolacta Bioscience, Inc.

    Biopharmaceutical company developing and marketing human milk-based nutritional products for premature infants in the neonatal intensive care unit

    • Year Invested

      2016

    • Fund

      IV

    • Sector

      Biopharma

    • Company Status

      private

    • Investment Status

      current

    • Location

      City of Industry, CA

    • Website

      prolacta.com

  • Promentis Pharmaceuticals, Inc.

    Biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system disorders of System XC-

    • Year Invested

      2016

    • Fund

      IV

    • Sector

      Biopharma

    • Company Status

      private

    • Investment Status

      current

    • Location

      Milwaukee, WI

    • Website

      promentispharma.com

  • Protagonist Therapeutics, Inc.

    NasdaqGM:PTGX
    Clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based new chemical entities to address significant unmet medical needs in inflammatory bowel diseases

    • Year Invested

      2016

    • Fund

      IV

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      historic

    • Location

      Milpitas, CA

    • Website

      protagonist-inc.com

  • Quintiles Transnational Holdings Inc.

    NYSE:Q
    Contract pharmaceutical research and sales organization

    • Year Invested

      2003

    • Fund

      I

    • Sector

      Services

    • Company Status

      public

    • Investment Status

      historic

    • Location

      Durham, NC

    • Website

      quintiles.com

  • Roka Bioscience, Inc.

    NasdaqGM:ROKA
    Molecular diagnostics company focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens

    • Year Invested

      2011

    • Fund

      III

    • Sector

      Diagnostics

    • Company Status

      public

    • Investment Status

      historic

    • Location

      Warren, NJ

    • Website

      rokabio.com

  • Seragon Pharmaceuticals, Inc.

    Biopharmaceutical company focused on developing drugs for the treatment of estrogen receptor dependent breast cancer

    • Year Invested

      2013

    • Fund

      III

    • Sector

      Biopharma

    • Company Status

      acquired

    • Investment Status

      historic

    • Location

      San Diego, CA

    • Website

      gene.com

  • Sirion Therapeutics, Inc.

    Ophthalmic-focused biopharmaceutical company engaged in the discovery, development and commercialization of products for the protection and preservation of eyesight

    • Year Invested

      2007

    • Fund

      II

    • Sector

      Biopharma

    • Company Status

      acquired

    • Investment Status

      historic

    • Location

      Tampa, FL

    • Website

      N/A

  • SkinMedica, Inc.

    Specialty pharmaceutical company focused on development and commercialization of dermatology drugs and cosmeceuticals

    • Year Invested

      2004

    • Fund

      I

    • Sector

      Consumer

    • Company Status

      acquired

    • Investment Status

      historic

    • Location

      Carlsbad, CA

    • Website

      skinmedica.com

  • Sorrento Therapeutics, Inc.

    NasdaqCM:SRNE
    Biopharmaceutical company engaged in the discovery, acquisition, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs

    • Year Invested

      2013

    • Fund

      III

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      historic

    • Location

      San Diego, CA

    • Website

      sorrentotherapeutics.com

  • Spirox, Inc.

    Medical device company that is focused on developing minimally invasive technologies that improve the quality of life for patients with nasal obstruction

    • Year Invested

      2015

    • Fund

      III

    • Sector

      Medical Device

    • Company Status

      acquired

    • Investment Status

      historic

    • Location

      Menlo Park, CA

    • Website

      spiroxmed.com

  • Sunesis Pharmaceuticals, Inc.

    NasdaqCM:SNSS
    Biopharmaceutical company developing oncology therapeutics for the treatment of solid and hematologic cancers

    • Year Invested

      2016

    • Fund

      IV

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      current

    • Location

      San Francisco, CA

    • Website

      sunesis.com

  • Synergy Pharmaceuticals Inc.

    NasdaqGS:SGYP
    Biopharmaceutical company focused on the development of novel therapies based on the natural human hormone, uroguanylin, to treat gastrointestinal (GI) diseases and disorders

    • Year Invested

      2014

    • Fund

      III

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      historic

    • Location

      New York, NY

    • Website

      synergypharma.com

  • Syros Pharmaceuticals, Inc.

    NasdaqGS:SYRS
    Life sciences company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases

    • Year Invested

      2014

    • Fund

      III

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      historic

    • Location

      Watertown, MA

    • Website

      syros.com

  • T2 Biosystems, Inc.

    NasdaqGM:TTOO
    In vitro diagnostics company that has developed a technology platform that offers a rapid, sensitive and simple alternative to existing diagnostic methodologies

    • Year Invested

      2011

    • Fund

      III

    • Sector

      Diagnostics

    • Company Status

      public

    • Investment Status

      historic

    • Location

      Lexington, MA

    • Website

      t2biosystems.com

  • Topaz Pharmaceuticals, Inc.

    Specialty pharmaceutical company focused on developing and commercializing treatments primarily for the pediatric and dermatology markets.

    • Year Invested

      2007

    • Fund

      II

    • Sector

      Biopharma

    • Company Status

      acquired

    • Investment Status

      historic

    • Location

      Horsham, PA

    • Website

      sanofi.us

  • TransEnterix, Inc.

    NYSEMKT:TRXC
    Medical device company that is focused on the development and commercialization of manual and robotic assisted surgical systems for minimally invasive surgery

    • Year Invested

      2009

    • Fund

      III

    • Sector

      Medical Device

    • Company Status

      public

    • Investment Status

      current

    • Location

      Morrisville, NC

    • Website

      transenterix.com

  • TRIA Beauty, Inc.

    Medical device company developing and commercializing at-home, light-based skincare products

    • Year Invested

      2008

    • Fund

      II

    • Sector

      Consumer

    • Company Status

      private

    • Investment Status

      historic

    • Location

      Dublin, CA

    • Website

      triabeauty.com

  • Verona Pharma plc

    NasdaqGM:VRNA
    UK-based biopharmaceutical company focused on the development of innovative prescription medicines to treat respiratory diseases with significant medical unmet needs

    • Year Invested

      2016

    • Fund

      IV

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      current

    • Location

      London, UK

    • Website

      veronapharma.com

  • Versartis, Inc.

    NasdaqGS:VSAR
    Endocrine-focused biopharmaceutical company developing novel long-acting recombinant human growth hormone for growth hormone deficiency

    • Year Invested

      2013

    • Fund

      III

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      historic

    • Location

      Redwood City, CA

    • Website

      versartis.com

  • ViewRay, Inc.

    NasdaqGM:VRAY
    Medical device company developing advanced radiation therapy technology for the treatment of cancer

    • Year Invested

      2008

    • Fund

      II

    • Sector

      Medical Device

    • Company Status

      public

    • Investment Status

      historic

    • Location

      Oakwood Village, OH

    • Website

      viewray.com

  • VIVUS, Inc.

    NasdaqGS:VVUS
    Biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes, sleep apnea and sexual health

    • Year Invested

      2006

    • Fund

      II

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      historic

    • Location

      Mountain View, CA

    • Website

      vivus.com

  • Zavante Therapeutics, Inc.

    Biopharmaceutical company focused on novel products that address serious unmet medical needs in the hospital

    • Year Invested

      2016

    • Fund

      IV

    • Sector

      Biopharma

    • Company Status

      acquired

    • Investment Status

      historic

    • Location

      San Diego

    • Website

      zavante.com

  • ZELTIQ Aesthetics, Inc.

    NasdaqGS:ZLTQ
    Medical technology company focused on developing and commercializing products utilizing a controlled cooling technology platform for non-invasive fat reduction

    • Year Invested

      2010

    • Fund

      III

    • Sector

      Consumer

    • Company Status

      acquired

    • Investment Status

      historic

    • Location

      Pleasanton, CA

    • Website

      coolsculpting.com

  • Zosano Pharma Corporation

    NasdaqCM:ZSAN
    Biopharmaceutical company developing a novel patch formulation of zolmitriptan for the treatment of acute migraine

    • Year Invested

      2018

    • Fund

      IV

    • Sector

      Biopharma

    • Company Status

      public

    • Investment Status

      current

    • Location

      Fremont, CA

    • Website

      zosanopharma.com